Beijing SL Pharmaceutical Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022	Dec '20 Dec 31, 2020
Cash & Equivalents	383.95	411.96	683.83	595.04	827.84	663.48
Short-Term Investments	-	1,089	840.62	713.36	646.23	605.63
Trading Asset Securities	569.63	480.86	608.56	144.91	162.36	173.81
Cash & Short-Term Investments	953.57	1,982	2,133	1,453	1,636	1,443
Cash Growth	3.52%	-7.07%	46.77%	-11.19%	13.41%	-24.62%
Accounts Receivable	90.66	105.79	200.57	254.86	357.56	466.08
Other Receivables	14.91	15.65	35.25	31.35	21.6	2.9
Receivables	105.56	121.44	235.82	286.2	379.16	468.98
Inventory	394.81	246.33	144.46	136.82	124.83	112.03
Other Current Assets	1,132	138.8	126.69	121.34	157.31	183.4
Total Current Assets	2,586	2,489	2,640	1,998	2,298	2,207
Property, Plant & Equipment	533.23	514.24	503.34	527.3	604.01	589.16
Long-Term Investments	1,222	1,578	1,573	1,798	1,404	1,251
Other Intangible Assets	683.98	678.58	693.77	526.36	479.46	423.38
Long-Term Deferred Tax Assets	64.08	69.52	-	39.5	27.65	25.35
Long-Term Deferred Charges	489.85	519	451.89	454.42	394.72	291.84
Other Long-Term Assets	449.13	130.49	415.6	532.22	553.25	606.28
Total Assets	6,029	5,979	6,278	5,876	5,760	5,395
Accounts Payable	55.35	122.29	250.76	176.18	191.4	179.93
Accrued Expenses	36.57	45.82	46.93	30.32	31.8	25.23
Short-Term Debt	-	-	-	-	-	5.51
Current Portion of Leases	-	-	-	-	0.25	-
Current Income Taxes Payable	2.07	0.18	0	2.61	4.48	4.28
Current Unearned Revenue	75.6	70.53	15.29	27.87	13.33	10.01
Other Current Liabilities	39.46	50.59	60.34	51.85	83.71	90.02
Total Current Liabilities	209.04	289.41	373.33	288.83	324.96	314.98
Long-Term Leases	-	-	-	-	2.22	-
Long-Term Unearned Revenue	41.17	44	47.04	51.38	56.23	60.97
Long-Term Deferred Tax Liabilities	77.75	64.97	47.36	56.39	50.82	34.15
Total Liabilities	327.96	398.37	467.72	396.6	434.23	410.09
Common Stock	1,027	1,027	1,027	1,027	1,027	1,027
Additional Paid-In Capital	49.62	49.62	49.62	43.85	32.58	17.59
Retained Earnings	4,603	4,482	4,710	4,396	4,265	3,941
Comprehensive Income & Other	13.47	13.47	13.47	0.67	-12.99	-11.68
Total Common Equity	5,693	5,572	5,801	5,468	5,311	4,975
Minority Interest	7.73	8.2	9.42	11.16	14.73	10.13
Shareholders' Equity	5,701	5,581	5,810	5,479	5,326	4,985
Total Liabilities & Equity	6,029	5,979	6,278	5,876	5,760	5,395
Total Debt	-	-	-	-	2.47	5.51
Net Cash (Debt)	953.57	1,982	2,133	1,453	1,634	1,437
Net Cash Growth	3.52%	-7.07%	46.77%	-11.06%	13.67%	-24.75%
Net Cash Per Share	0.90	1.87	2.10	1.43	1.57	1.42
Filing Date Shares Outstanding	1,027	1,027	1,027	1,027	1,027	1,027
Total Common Shares Outstanding	1,027	1,027	1,027	1,027	1,027	1,027
Working Capital	2,377	2,199	2,267	1,709	1,973	1,892
Book Value Per Share	5.54	5.42	5.65	5.32	5.17	4.84
Tangible Book Value	5,009	4,894	5,107	4,942	4,832	4,551
Tangible Book Value Per Share	4.88	4.76	4.97	4.81	4.70	4.43
Buildings	-	434.54	437.22	430.73	452.32	457.05
Machinery	-	472.98	458.48	435.39	415.76	388.59
Construction In Progress	-	94.92	56.97	64.75	99.87	67.7

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.